GMED - GenoMed Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GMED - GenoMed Inc.

GMED 83.90

+36.0%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Tadsamillionaire	1/20/2005 7:39:56 AM
	of 347

There are 20 million patients in the U.S. with diabetes. The annual cost of their care exceeds $100 billion.Dr. David Moskowitz, GenoMed's Chairman and Chief Medical Officer, said, "This paper speculates on the biochemical mechanism of how ACE leads not only to diabetes but to all its complications. It will require experimental confirmation in the laboratory, although clinical confirmation already exists. Meanwhile, the paper establishes a rationale for using effective tissue ACE inhibition in all diabetic patients, not just those with early kidney failure. Controlling sugar levels without fully inhibiting tissue ACE may explain why patients with diabetes still have such dismal outcomes."Dr. Moskowitz continued, "This paper explains how a hydrophobic ACE inhibitor like ramipril could actually prevent diabetes, as was found unexpectedly in the HOPE trial published in the New England Journal of Medicine in January, 2001. This paper says why our treatment approach should be extended to the 60 million Americans with high blood pressure, who are at increased risk of developing diabetes, so as to prevent their getting diabetes at all." forrelease.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next